Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInventory AverageInvested CapitalMarket Capitalization

RedHill Biopharma (RDHL) Gross Margin: 2014-2024

Historic Gross Margin for RedHill Biopharma (RDHL) over the last 10 years, with Dec 2024 value amounting to 60.31%.

  • RedHill Biopharma's Gross Margin rose 415.00% to 55.12% in Q2 2023 from the same period last year, while for Jun 2023 it was 42.74%, marking a year-over-year increase of 111.00%. This contributed to the annual value of 60.31% for FY2024, which is 1328.00% up from last year.
  • Per RedHill Biopharma's latest filing, its Gross Margin stood at 60.31% for FY2024, which was up 28.25% from 47.03% recorded in FY2023.
  • RedHill Biopharma's Gross Margin's 5-year high stood at 60.31% during FY2024, with a 5-year trough of 42.39% in FY2021.
  • For the 3-year period, RedHill Biopharma's Gross Margin averaged around 51.13%, with its median value being 47.03% (2023).
  • As far as peak fluctuations go, RedHill Biopharma's Gross Margin slumped by 2,141bps in 2020, and later spiked by 1,328bps in 2024.
  • RedHill Biopharma's Gross Margin (Yearly) stood at 42.68% in 2020, then dropped by 29bps to 42.39% in 2021, then spiked by 367bps to 46.06% in 2022, then surged by 97bps to 47.03% in 2023, then skyrocketed by 1,328bps to 60.31% in 2024.